Saranac Partners’s Eli Lilly LLY Stock Holding History

Saranac Partners’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-316	Closed	-$244K	–	83
2024 Q4	$244K	Buy	+316	New	+$262K	0.13%	68

Other funds holding LLY

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Saranac Partners's LLY Position: Q1 2025 in Review

Saranac Partners sold out of Eli Lilly (LLY) in Q1 2025, closing a stake of 316 shares — an estimated $244K sold.

Saranac Partners first reported a position in LLY in Q4 2024 and held it in 1 quarter. The position peaked at $244K in Q4 2024. 3,920 funds tracked by Wall St. Rank hold LLY as of Q1 2025.

Saranac Partners reported no remaining Eli Lilly position as of Q1 2025 after selling out during the quarter.
Saranac Partners sold 316 Eli Lilly shares in Q1 2025, an estimated $244K.
Saranac Partners first reported a position in Eli Lilly in Q4 2024 and held it in 1 quarter.
Saranac Partners's Eli Lilly position peaked at $244K in Q4 2024.
3,920 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2025.

Based on Saranac Partners's 13F filing for Q1 2025, filed 15 Dec 2025.